Nuclear Localization of PTEN by a Ran-dependent Mechanism Enhances Apoptosis: Involvement of an N-terminal Nuclear Localization Domain and Multiple Nuclear Exclusion Motifs

Overview

Journal Mol Biol Cell

Specialties Cell Biology
Molecular Biology

Date 2006 Jun 30

PMID 16807353

Citations 69

Authors

Anabel Gil

Amparo Andres-Pons

Elena Fernandez

Miguel Valiente

Josema Torres

Javier Cervera

Rafael Pulido

Affiliations

Soon will be listed here.

Abstract

The targeting of the tumor suppressor PTEN protein to distinct subcellular compartments is a major regulatory mechanism of PTEN function, by controlling its access to substrates and effector proteins. Here, we investigated the molecular basis and functional consequences of PTEN nuclear/cytoplasmic distribution. PTEN accumulated in the nucleus of cells treated with apoptotic stimuli. Nuclear accumulation of PTEN was enhanced by mutations targeting motifs in distinct PTEN domains, and it was dependent on an N-terminal nuclear localization domain. Coexpression of a dominant negative Ran GTPase protein blocked PTEN accumulation in the nucleus, which was also affected by coexpression of importin alpha proteins. The lipid- and protein-phosphatase activity of PTEN differentially modulated PTEN nuclear accumulation. Furthermore, catalytically active nuclear PTEN enhanced cell apoptotic responses. Our findings indicate that multiple nuclear exclusion motifs and a nuclear localization domain control PTEN nuclear localization by a Ran-dependent mechanism and suggest a proapoptotic role for PTEN in the cell nucleus.

Citing Articles

Deep learning prioritizes cancer mutations that alter protein nucleocytoplasmic shuttling to drive tumorigenesis.

Zheng Y, Yu K, Lin J, Liang Z, Zhang Q, Li J Nat Commun. 2025; 16(1):2511.

PMID: 40087285 DOI: 10.1038/s41467-025-57858-8.

Potentiation by Protein Synthesis Inducers of Translational Readthrough of Pathogenic Premature Termination Codons in PTEN Isoforms.

Torices L, Nunes-Xavier C, Pulido R Cancers (Basel). 2024; 16(16).

PMID: 39199607 PMC: 11352852. DOI: 10.3390/cancers16162836.

Spatiotemporal distribution of PTEN before directed cell migration in monolayers.

Lu Q, Sasaki S, Sera T, Kudo S In Vitro Cell Dev Biol Anim. 2024; 60(10):1160-1173.

PMID: 38926230 DOI: 10.1007/s11626-024-00927-x.

Hyperphosphorylated PTEN exerts oncogenic properties.

van Ree J, Jeganathan K, Fierro Velasco R, Zhang C, Can I, Hamada M Nat Commun. 2023; 14(1):2983.

PMID: 37225693 PMC: 10209192. DOI: 10.1038/s41467-023-38740-x.

Nuclear PTEN's Functions in Suppressing Tumorigenesis: Implications for Rare Cancers.

Langdon C Biomolecules. 2023; 13(2).

PMID: 36830628 PMC: 9953540. DOI: 10.3390/biom13020259.

References

Mayo L, Dixon J, Durden D, Tonks N, Donner D . PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem. 2001; 277(7):5484-9. DOI: 10.1074/jbc.M108302200. View

Waite K, Eng C . Protean PTEN: form and function. Am J Hum Genet. 2002; 70(4):829-44. PMC: 379112. DOI: 10.1086/340026. View

Whiteman D, Zhou X, Cummings M, Pavey S, Hayward N, Eng C . Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int J Cancer. 2002; 99(1):63-7. DOI: 10.1002/ijc.10294. View

Iijima M, Devreotes P . Tumor suppressor PTEN mediates sensing of chemoattractant gradients. Cell. 2002; 109(5):599-610. DOI: 10.1016/s0092-8674(02)00745-6. View

Funamoto S, Meili R, Lee S, Parry L, Firtel R . Spatial and temporal regulation of 3-phosphoinositides by PI 3-kinase and PTEN mediates chemotaxis. Cell. 2002; 109(5):611-23. DOI: 10.1016/s0092-8674(02)00755-9. View

Birle D, Bottini N, Williams S, Huynh H, deBelle I, Adamson E . Negative feedback regulation of the tumor suppressor PTEN by phosphoinositide-induced serine phosphorylation. J Immunol. 2002; 169(1):286-91. DOI: 10.4049/jimmunol.169.1.286. View

Mayo L, Donner D . The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci. 2002; 27(9):462-7. DOI: 10.1016/s0968-0004(02)02166-7. View

Miller S, Lou D, Seldin D, Lane W, Neel B . Direct identification of PTEN phosphorylation sites. FEBS Lett. 2002; 528(1-3):145-53. DOI: 10.1016/s0014-5793(02)03274-x. View

Orchiston E, Bennett D, Leslie N, Clarke R, Winward L, Downes C . PTEN M-CBR3, a versatile and selective regulator of inositol 1,3,4,5,6-pentakisphosphate (Ins(1,3,4,5,6)P5). Evidence for Ins(1,3,4,5,6)P5 as a proliferative signal. J Biol Chem. 2003; 279(2):1116-22. DOI: 10.1074/jbc.M310933200. View

10.

Sumitomo M, Iwase A, Zheng R, Navarro D, Kaminetzky D, Shen R . Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. Cancer Cell. 2004; 5(1):67-78. DOI: 10.1016/s1535-6108(03)00331-3. View

11.

Raftopoulou M, Etienne-Manneville S, Self A, Nicholls S, Hall A . Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. Science. 2004; 303(5661):1179-81. DOI: 10.1126/science.1092089. View

12.

Xu L, Massague J . Nucleocytoplasmic shuttling of signal transducers. Nat Rev Mol Cell Biol. 2004; 5(3):209-19. DOI: 10.1038/nrm1331. View

13.

Walker S, Leslie N, Perera N, Batty I, Downes C . The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif. Biochem J. 2004; 379(Pt 2):301-7. PMC: 1224073. DOI: 10.1042/BJ20031839. View

14.

Mahimainathan L, Ghosh Choudhury G . Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase. J Biol Chem. 2004; 279(15):15258-68. DOI: 10.1074/jbc.M314328200. View

15.

Iijima M, Huang Y, Luo H, Vazquez F, Devreotes P . Novel mechanism of PTEN regulation by its phosphatidylinositol 4,5-bisphosphate binding motif is critical for chemotaxis. J Biol Chem. 2004; 279(16):16606-13. DOI: 10.1074/jbc.M312098200. View

16.

Parsons R . Human cancer, PTEN and the PI-3 kinase pathway. Semin Cell Dev Biol. 2004; 15(2):171-6. DOI: 10.1016/j.semcdb.2003.12.021. View

17.

Sansal I, Sellers W . The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol. 2004; 22(14):2954-63. DOI: 10.1200/JCO.2004.02.141. View

18.

Leslie N, Downes C . PTEN function: how normal cells control it and tumour cells lose it. Biochem J. 2004; 382(Pt 1):1-11. PMC: 1133909. DOI: 10.1042/BJ20040825. View

19.

Ahn J, Rong R, Liu X, Ye K . PIKE/nuclear PI 3-kinase signaling mediates the antiapoptotic actions of NGF in the nucleus. EMBO J. 2004; 23(20):3995-4006. PMC: 524338. DOI: 10.1038/sj.emboj.7600392. View

20.

Yu Z, Fotouhi-Ardakani N, Wu L, Maoui M, Wang S, Banville D . PTEN associates with the vault particles in HeLa cells. J Biol Chem. 2002; 277(43):40247-52. DOI: 10.1074/jbc.M207608200. View